Charles Olson
Director/Board Member bij EDESA BIOTECH, INC.
Vermogen: - $ op 31-03-2024
Profiel
Charles V.
Olson is currently the Director at Edesa Biotech, Inc. and President at Alkira Therapeutics, Inc. Previously, he held positions such as Chief Operating Officer at Dendreon Corp., Vice President at NGM Biopharmaceuticals, Inc., and Senior Vice President at Ansun Biopharma, Inc. He also served as Director at Onyx Pharmaceuticals, Inc. and Independent Director at Stellar Biotechnologies, Inc. Additionally, he has a background in manufacturing and technology, having worked as Vice President at Cell Genesys, Inc. and Senior Director at BioMarin Pharmaceutical, Inc. He holds a graduate degree from the University of California, Santa Barbara, an undergraduate degree from Westmont College, and a doctorate from Hawthorn University.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
EDESA BIOTECH, INC.
-.--% | 02-04-2024 | 0 ( -.--% ) | - $ | 31-03-2024 |
Actieve functies van Charles Olson
Bedrijven | Functie | Begin |
---|---|---|
EDESA BIOTECH, INC. | Director/Board Member | 23-05-2023 |
Alkira Therapeutics, Inc.
Alkira Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Anthera Pharmaceuticals, Inc., Alkira Therapeutics, Inc. develops and commercializes clinical pharmaceutical products. The private company is based in Hayward, CA. | President | - |
Eerdere bekende functies van Charles Olson
Bedrijven | Functie | Einde |
---|---|---|
DENDREON CORPORATION | Chief Operating Officer | 01-04-2023 |
APPLIED MOLECULAR TRANSPORT INC. | Chief Operating Officer | 16-05-2022 |
ANTHERA PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 13-07-2017 |
Ansun Biopharma, Inc.
Ansun Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ansun Biopharma, Inc. manufactures pharmaceutical products. Its products include Fludase, a drug candidate for the prophylaxis and treatment of respiratory infections caused by various types of influenza virus, including the types of virus that may cause a potential influenza pandemic, as well as various types of parainfluenza virus. The company was founded by Nancy Chang on August 9, 2012 and is headquartered in San Diego, CA. | Corporate Officer/Principal | - |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Corporate Officer/Principal | - |
Opleiding van Charles Olson
University of California, Santa Barbara | Graduate Degree |
Westmont College | Undergraduate Degree |
Hawthorn University | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 5 |
---|---|
BIOMARIN PHARMACEUTICAL INC. | Health Technology |
ANTHERA PHARMACEUTICALS, INC. | Health Technology |
NGM BIOPHARMACEUTICALS, INC. | Health Technology |
APPLIED MOLECULAR TRANSPORT INC. | Health Technology |
EDESA BIOTECH, INC. | Health Technology |
Bedrijven in privébezit | 6 |
---|---|
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | Health Technology |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Health Technology |
Dendreon Corp.
Dendreon Corp. Medical SpecialtiesHealth Technology Dendreon Corp. discovers, develops and commercializes novel products for the treatment of cancer. The company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy ACI product candidates designed to stimulate an immune response in a variety of tumor types. It is an exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. Dendreon was founded by Christopher S. Henney, Edgar G. Engleman and Samuel Strober in 1992 and is headquartered in Seattle, WA. | Health Technology |
Stellar Biotechnologies, Inc.
Stellar Biotechnologies, Inc. Pharmaceuticals: MajorHealth Technology Stellar Biotechnologies, Inc. engages in the research, development, manufacture, and commercialization of Keyhole Limpet Hemocyanin (KLH), an immune-stimulating protein utilized as a carrier molecule in therapeutic vaccines and for assessing immune system function. Its product portfolio includes Stellar KLH Products, Stellar KLH Protein, and Stellar KLH ELISA Kits. The Company was founded in 1999 and is headquartered in Port Hueneme, CA. | Health Technology |
Alkira Therapeutics, Inc.
Alkira Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Anthera Pharmaceuticals, Inc., Alkira Therapeutics, Inc. develops and commercializes clinical pharmaceutical products. The private company is based in Hayward, CA. | Health Technology |
Ansun Biopharma, Inc.
Ansun Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ansun Biopharma, Inc. manufactures pharmaceutical products. Its products include Fludase, a drug candidate for the prophylaxis and treatment of respiratory infections caused by various types of influenza virus, including the types of virus that may cause a potential influenza pandemic, as well as various types of parainfluenza virus. The company was founded by Nancy Chang on August 9, 2012 and is headquartered in San Diego, CA. | Health Technology |